ORIGINAl ARTiCLE

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

Christien Rondaan,1,2 Victoria Furer,3,4 Marloes W Heijstek,5 Nancy Agmon-Levin,4,6 Marc Bijl,7 Ferdinand C Breedveld,8 Raffaele D’Amelio,9 Maxime Dougados,10,11 Meliha C Kapetanovic,12 Jacob M van Laar,13 Annette Ladeoged de Thurah,14 Robert Landewe,15,16 Anna Molto,8,10 Ulf Müller-Ladner,17 Karen Schreiber,18,19 Leo Smolar,20 Jim Walker,21 Klaus Warnatz,22 Nico M Wulffraat,23 Sander van Assen,24 Ori Elkayam3,4

ABSTRACT

Aim To present a systematic literature review (SLR) on efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) aiming to provide a basis for updating the EULAR evidence-based recommendations.

Methods An SLR was performed according to the standard operating procedures for EULAR-endorsed recommendations. Outcome was determined by efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD, including those receiving immunomodulating therapy. Furthermore, a search was performed on the effect of vaccinating household members of patients with AIIRD on the occurrence of vaccine-preventable infections in patients and their household members (including newborns). The literature search was performed using Medline, Embase and the Cochrane Library (October 2009 to August 2018).

Results While most investigated vaccines were efficacious and/or immunogenic in patients with AIIRD, some were less efficacious than in healthy control subjects, and/or in patients receiving immunosuppressive agents. Adverse events of vaccination were generally mild and the rates were comparable to those in healthy persons. Vaccination did not seem to lead to an increase in activity of the underlying AIIRD, but insufficient power of most studies precluded arriving at definite conclusions. The number of studies investigating clinical efficacy of vaccination is still limited. No studies on the effect of vaccinating household members of patients with AIIRD were retrieved.

Conclusion Evidence on efficacy, immunogenicity and safety of vaccination in patients with AIIRD was systematically reviewed to provide a basis for updated recommendations.

INTRODUCTION

Infectious diseases and associated complications comprise an important cause of morbidity and mortality in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Increased susceptibility to infectious diseases in these patients is most likely due to an immunomodulating effect of the disease itself and/or by use of immunosuppressive medications.1

Key messages

What is already known about this subject?

► Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at increased risk of vaccine-preventable infections and associated complications.

► Vaccination may be less efficacious in (subgroups of) patients with AIIRD and could potentially lead to exacerbation of underlying disease.

► Evidence-based recommendations of the EULAR for vaccination of adult patients with AIIRD were published in 2011.

What does this study add?

► This systematic literature review summarises available evidence on efficacy, immunogenicity and safety of vaccination in AIIRD since October 2009, providing a basis for updated EULAR recommendations.

How might this impact on clinical practice?

► The aim of the updated recommendations is to aid health professionals dealing with questions regarding vaccination in patients with AIIRD, whereby reducing infection-related morbidity and mortality.
Vaccination is generally regarded as a safe, efficacious and low-cost method for preventing certain infections. However, vaccination may be less efficacious in (subgroups of) patients with AIIRD, as a result of their immunosuppressed state, and, moreover, could potentially lead to exacerbation of the underlying AIIRD.

In 2011, evidence-based recommendations for vaccination in patients with AIIRD were published. They were formulated by an EULAR task force to aid health professionals dealing with questions regarding vaccination in patients with AIIRD in daily clinical practice, with the aim of reducing infection-related morbidity and mortality in these patients.3 The authors stated that the recommendations needed to be updated on a regular basis as new evidence becomes available.2 Towards this end, the League commissioned another multidisciplinary task force with the purpose of formulating up-to-date recommendations for vaccination in patients with AIIRD.

The current report presents the results of an SLR on incidence and prevalence of VPIs in patients with AIIRD,4 as well as on the efficacy of vaccination in patients with AIIRD, including those using immunomodulating agents. Together with the results of an SLR on the occurrence of VPIs in patients with AIIRD,1 the current SLR provided the task force with a basis for updating the recommendations.3

**METHODS**

The work was performed in accordance with the 2014 EULAR standard operating procedures for EULAR-endorsed recommendations.4

The expert committee first formulated four main research questions (Box 1), based on the 2011 version of the recommendations. The current review reports on the SLR results of three of these four questions, which include the topics of efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD (including those receiving immunosuppressive agents) and the effect of vaccinating their household members on the occurrence of VPIs in both patients and their household members (including newborns). The efficacy of vaccination was defined as the capacity to prevent infections, while the immunogenicity of vaccination refers to the capacity to induce vaccine-specific humoral and/or cellular immune responses. Safety of vaccination in the AIIRD population was determined by the assessment of both the occurrence of adverse effects and the influence on the underlying disease.5

Next, the research questions were adapted according to the PICO-method (population-intervention-comparison-outcome). Population, intervention, comparison and outcome definitions were combined and adapted to be used as search terms (table 1). Medline (via Pubmed), Embase and the Cochrane Library were searched from October 2009 to August 2018. Meta-analyses, randomised trials, cohort studies and case series with at least five participants were eligible. Only English articles on adult patients (≥18 years) were included. Papers with non-original data, case reports, case series with less than five patients, abstracts presented in scientific meetings, and papers included in the previous version of these recommendations were excluded. Papers that were not retrieved in the search, but were relevant in the opinion of the committee, could be added. See figure 1 for the flow chart displaying the search strategy for PICO 2 and 3.

For some of the AIIRD, immunomodulating agents and vaccines (diptheria, pertussis, measles, mumps, rubella, Neisseria meningitides, Haemophilus influenzae B and typhoid fever vaccine) that were included in the literature search, no relevant articles were retrieved. No relevant articles were retrieved in the search on the effect of vaccinating household members of patients with AIIRD (research question 4).

Data analysis was performed by CR, VF, MH, SvA and OE. The following information was retrieved from all included articles: name of first author, year of publication, country where the study was performed, years of data inclusion, type of study, vaccine used, addition of adjuvant, type of AIIRD, number of participants, age and sex of participants, disease duration, time of follow-up, medication used and outcome of vaccination (efficacy, immunogenicity and/or safety). The articles were critically assessed (online supplementary file S6—included articles and critical appraisal) by applying tools from the Cochrane Library (online supplementary file S7—critical appraisal criteria) and given a level of evidence based on the Oxford Centre for Evidence-based Medicine approach (table 2). Discrepancies between reviewers were resolved by consensus. The final recommendations were graded according to the level of evidence of the underlying articles (table 3).

**RESULTS**

**Influenza vaccination**

**Efficacy—immunogenicity—safety**

Up to the previous recommendations, one study addressed the issue of efficacy of influenza vaccination in patients with AIIRD.6 Immunogenicity of the vaccine had been evaluated in 26 studies, mainly including patients with rheumatoid arthritis (RA), systemic lupus
### Table 1  Formulation of PICO-questions

**Q2: What is the efficacy, immunogenicity and safety of available vaccines in adult patients with AIIRD?**

**Population:** patients with AIIRD*

**Intervention:** immunisation/vaccination with vaccines suitable for adults**

**Comparison:** healthy controls, non-vaccinated patients with AIIRD or none

**Outcome:** efficacy (prevention of vaccine-preventable disease), immunogenicity (laboratory markers for vaccine efficacy, eg, seroprotection/seroconversion) and safety (effect on the underlying autoimmune disease or adverse effects from vaccination)

**Q3: Are vaccines efficacious and immunogenic in adult patients with AIIRD, treated with immunosuppressive agents and disease-modifying antirheumatic drugs (DMARDs)?**

**Population:** patients with AIIRD* using immunomodulating agents***

**Intervention:** immunisation/vaccination with vaccines suitable for adults**

**Comparison:** healthy controls, patients with AIIRD not using analysed agents or none

**Outcome:** efficacy (prevention of vaccine-preventable disease), immunogenicity (laboratory markers for vaccine efficacy, eg, seroprotection/seroconversion)

**Q4: What is the effect of vaccinating household members of patients with AIIRD on the occurrence of VPI in both the patients and household members (including newborns)?**

**Population:** patients with AIIRD*

**Intervention:** immunisation/vaccination of household contacts of patients with AIIRD with vaccines suitable for children and adults**

**Comparison:** patients with AIIRD with non-vaccinated household members

**Outcome:** incidence of VPI in patients with AIIRD/safety of household vaccine for patients with AIIRD

| **AIIRD** | **Vaccines** | **Immunomodulating agents** |
|-----------|--------------|----------------------------|
| Rheumatoid arthritis | Influenza | Glucocorticosteroids |
| Systemic lupus erythematosus | Tetanus toxoid | Methotrexate |
| Antiphospholipid syndrome | Diphtheria | Sulfasalazine |
| Adult Still’s disease | Pertussis | Leflunomide |
| Systemic sclerosis | Measles | Hydroxychloroquine |
| Sjögren syndrome | Mumps | Azathioprine |
| Mixed connective tissue diseases | Rubella | Mycophenolic preparation |
| Relapsing polychondritis | Varicella-zoster virus | Ciclosporine |
| Giant cell arteritis | Human papillomavirus | Tacrolimus |
| Polymyalgia rheumatica | *Streptococcus pneumoniae* | Cyclophosphamide |
| Takayasu arteritis | Hepatitis A | Rituximab |
| Polyaartitis nodosa | Hepatitis B | Beclomethasone |
| ANCA-associated vasculitis | *Neisseria meningitidis* | Abatacept |
| Microscopic polyangiitis | *Haemophilus influenzae B* | TNFα blocking agents |
| Granulomatosis with polyangiitis | Tickborne encephalitis | Infliximab |
| Eosinophilic granulomatosis with polyangiitis | Typhoid fever | Etanercept |
| Behçet’s disease | Yellow fever | Adalimumab |
| Anti-GBM disease | | Certolizumab |
| Cryoglobulinaemic syndrome | | Golimumab |
| Polymyositis | | Anti-IL-6 agents |
| Dermatomyositis | | Tocilizumab |
| Clinically amyotrophic dermatomyositis | | Sarilumab |
| Inclusion body myositis | | Anti-IL-17 agents |
| Antisynthetase syndrome | | Secukinumab |
| Eosinophilic myositis | | Ixekizumab |
| Eosinophilic fasciitis | | Anti-IL-1 agents |
| Spondyloarthropathies | | Canakinumab |
| Periodic fever syndromes | | Anakinra |
| Familial Mediterranean fever | | Rilonacept |
| TNF-receptor associated syndrome (TRAPS) | | Apremilast |
| Cryopyrin associated periodic syndrome (CAPS) | | Tofacitinib |

AIIRD, autoimmune inflammatory rheumatic disease(s); ANCA, antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; IL, interleukin; PICO, population-intervention-comparison-outcome; TNF, tumour necrosis factor; VPI, vaccine-preventable infection.
Figure 1  Flow chart displaying the search strategy for PICO 2 and 3. DMARDs, disease-modifying antirheumatic drugs; IS, immunosuppressives; PICO, population-intervention-comparison-outcome.

Table 2  Oxford Centre for Evidence-Based Medicine—levels of evidence

| Grade | Description |
|-------|-------------|
| 1a    | Systematic review (with homogeneity) of RCTs |
| 1b    | Individual RCT (with narrow CI) |
| 1c    | ‘All or none’ |
| 2a    | Systematic review (with homogeneity) of cohort studies |
| 2b    | Individual cohort study (including low-quality RCT) |
| 2c    | ‘Outcomes’ research, ecological studies |
| 3a    | Systematic review (with homogeneity) of case-control studies |
| 3b    | Individual case-control study |
| 4     | Case series (and poor quality cohort and case-control studies) |
| 5     | Expert opinion without explicit critical appraisal, or based on physiology, bench research of ‘first principles’ |

RCT, randomised controlled trial.

Table 3  Grades of recommendation

| Grade | Description |
|-------|-------------|
| A     | Consistent level 1 studies |
| B     | Consistent level 2 or 3 studies or extrapolations from level 1 studies |
| C     | Level 4 studies or extrapolations from level 2 or 3 studies |
| D     | Level 5 evidence or troublingly inconsistent or inconclusive studies of any level |

erythematosus (SLE) and granulomatosis with polyangiitis (GPA).7–32 Most of these studies demonstrated similar rates of immunogenicity among patients and healthy controls (HC), except for the studies in patients treated with rituximab, whose responses were severely impaired.12 14 33

From the previous recommendations up to August 2018, seven meta-analyses and 50 other studies have been published on efficacy, immunogenicity and safety of influenza vaccination, including the 2009 pandemic H1N1 influenza strain vaccine, in patients with AIIRD
Five studies addressed the efficacy of influenza vaccine.

Retrospective database analysis studies reported a reduced all-cause mortality rate and risk of hospitalisation for influenza-related complications in patients with RA,14 19 25 43–45 while another meta-analysis reported an adequate but lower response compared with HCs were also reported.21 26–29 Two meta-analyses including a total of 886 patients with RA and 685 controls concluded that 60%, 68% and 61% of patients with RA reached seroprotective antibody levels following influenza vaccination for the H1N1, H3N2 and B strain, respectively. Only for the H1N1 influenza strain, the strain for which most data were available, responses were significantly lower in patients than in HCs.32

Most studies on influenza vaccination in patients with AIIRD, however, address immunogenicity, mainly by assessing the development of a protective level of antibodies (titre value ≥40, as measured by the haemagglutination inhibition assay). For RA, most of these studies report similar responses in patients and HCs.7–9 15 20 38–41 A meta-analysis including a total of 886 patients with RA and 685 controls concluded that 60%, 68% and 61% of patients with RA reached seroprotective antibody levels following influenza vaccination for the H1N1, H3N2 and B strain, respectively. Only for the H1N1 influenza strain, the strain for which most data were available, responses were significantly lower in patients than in HCs.32

For SLE most studies report similar, adequate immune responses using trivalent seasonal subunit influenza vaccine,17 22–25 43 44 although modestly lower responses compared with HCs were also reported.21 26–29 Two meta-analyses reported an adequate but lower response against influenza A strains (H1N1 and H3N2) but not against influenza B in patients with SLE as compared with HCs,15 46 while another meta-analysis reported a reduced immunogenicity in SLE for H1N1 and B strains, but not for H3N2.47 Reported pooled seroprotection rates in patients with SLE are 66%–68%, 64%–76% and 60%–66% against H1N1, H3N2 and B strains, respectively.46 47

Likewise, in other AIIRD, including patients with spondyloarthropathies, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis and primary systemic sclerosis (pSS), adequate serological responses to influenza vaccination were found.30–32 48–53

Regarding the pandemic monovalent subunit influenza vaccine, most larger studies report reduced immunogenicity in patients with AIIRD (mostly RA and SLE), although protective antibody levels were reached in the majority of patients.41 52 54–68 A second booster dose of vaccine, given 3–4 weeks after the first, improved immunogenicity, resulting in seroprotection levels comparable to those of HCs.55 62 69 This phenomenon has also been shown in patients with SLE who received seasonal influenza vaccine for the first time.70 High disease activity levels did not preclude reaching seroprotection in a study that included 340 patients with RA, of which 14.5% had a DAS 28 (Disease Activity Score in 28 joints) value above 5.1.58

Influenza vaccination did not influence activity of the underlying AIIRD in patients with RA,71 72 74 91 SLE,6 19 21 25 30 37 39 45–47 ANCA-associated vasculitis or systemic sclerosis.72 80–82 Adverse events of influenza vaccination in patients with AIIRD were comparable to those in HCs in most studies,7 19 21 23 30 39 65 including a meta-analysis in patients with SLE.46 In contrast, a meta-analysis including 13 studies in patients with RA concluded that local, mild adverse events occurred significantly more frequently in patients with RA.32

Influence of immunomodulating agents

The influence of immunomodulating agents on influenza vaccine efficacy and immunogenicity is summarised in table 6. No influence of methotrexate (MTX) on influenza immunogenicity was found in most studies,30 40 45 62 72 74 including one meta-analysis in patients with RA.75 In some, a modest reduction in immunogenicity was observed.34–40 73 76 In another meta-analysis, results on the influence of MTX differed depending on whether response rates per influenza strain, or for at least two of the three strains, were analysed. In case of the latter approach, the negative impact of MTX was significant.77 Interestingly, temporary discontinuation of MTX was shown to significantly improve immunogenicity of seasonal influenza vaccination in patients with RA in two studies by Park et al.78 79 Discontinuation of MTX for 2 weeks after influenza vaccination led to a 11%–16% (depending on influenza strain) higher seroprotection rate compared with patients with RA who continued the use of MTX. Flare rates tended to be higher in patients with RA who temporarily halted MTX use, but the increase in disease activity was transient.78 79

Hydroxychloroquine does not influence the development of an adequate immune response to influenza vaccination.19 45 66 The same holds true for the use of TNF-α-blocking agents in the majority of studies,11 13 20 41 80 including two meta-analyses in RA.75 77 Another meta-analysis reported a lower seroprotection, but not seroconversion rate in patients with RA on anti-TNF α, only for the H1N1 influenza strain.82 Four studies did report a modestly reduced response to influenza vaccination in patients using anti-TNFα.10 16 40 60

B cell depletion therapy has been associated with hampered antibody responses following influenza vaccination in multiple studies. A negative influence of B cell depletion therapy was observed in two meta-analyses that pooled data from cohort studies. Patient numbers in analyses were low however, and Cs were wide.42 77 The interval between administration of rituximab and vaccination differed between studies. A study that included both patients with RA vaccinated 4–8 weeks (n=11) and 6–10 months after (n=12) the administration of rituximab demonstrated no response to influenza vaccination in the first, early group and a modestly restored response in the late group.14 The use of rituximab did not seem

(table 4 for seasonal trivalent and table 5 for monovalent pandemic influenza vaccination).
Table 4  Efficacy, immunogenicity and safety of trivalent influenza vaccination in patients with AIIRD (October 2009–August 2018)

| First author + ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff/imm. | LoE |
|---------------------|------|--------------|-----------|----------|----------------|--------|-----------------------------|-----|
| Subasinghe75        | 2018 | Meta-analysis | 7 studies in RA | – | See column influence of IS | – | MTX and anti-TNF not associated with reduced immunogenicity | 2a |
| Huang72             | 2017 | Meta-analysis | 13 studies in RA (also including pts <18 years) | – | Reduced immunogenicity RA compared with HCs for H1N1 strain, not for H3N2 and B | Disease activity not influenced by vaccination | GC: No influence Anti-TNF, RTX: Lower SP rate for H1N1, but not for SC or other strains | 2a 2a |
| Burmester21         | 2017 | Meta-analysis | Total in analysis: 171 RA-anti-TNF vacc. 382 RA-anti-TNF- non-vacc. All using adalimumab | Influenza-related AE occurred in 5% of vaccinated pts versus 14% of non-vacc. | – | – | 2a  |
| Hua77               | 2014 | Meta-analysis | 7 studies in RA | – | See column influence of IS | – | RTX: reduced immunogenicity Anti-TNF: no influence For MTX, results differed depending on method of analysis | 2a |
| Park79              | 2018 | RCT | 2 RA groups: 1. 156 MTX-cont. 2. 160 MTX hold for 2 weeks postvacc. | – | Better response for all strains in patients who hold MTX 2 weeks after vaccination (SP difference H1N1 11% (95% CI 2% to 19%), H3N2 16% (6% to 26%), B 14.7% (5% to 25%) | No SAE eight flares (5%) in MTX-cont. and 17 (11%) in MTX-hold group (p=0.07) | 4 |
| Park79              | 2017 | RCT | 4 RA groups on MTX: 1. 54 cont. 2. 44 hold 4 weeks pre, 3. 49 hold 2 weeks pre/2 weeks post 4. hold 4 weeks postvacc. | – | Adequate response Better results in pts who stopped MTX 2 weeks before and after vaccination | No SAE Flares tended to be more common in groups 2 and 3 (not significant) | – 2b |
| Kivitz290           | 2014 | RCT | 107 RA-CZP 109 RA-PCB | – | No difference | No difference in AE: 62.3% in PCB versus 65.6% in CZP, mostly mild/moderate Disease activity NR | Reduced on MTX | 1b-2b 4 |

Continued
| First author + ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff./imm. | LoE |
|----------------------|------|--------------|-----------|----------|----------------|--------|-----------------------------|-----|
| Chen34               | 2018 | Cohort (retrospective database) | 3748 RA-vacc 3748 RA non-vacc | Reduced risk of morbidity and mortality in vaccinated pts | – | – | 2b |
| Jain39               | 2017 | Cohort | 51 RA-MTX 51 RA-naïve 45 HCs | – | No difference | No influence on disease activity No difference in AE | See column immunogenicity | 2b 4 |
| Winthrop64 Part A    | 2016 | Cohort | 102 RA-TFC 98 RA-PCB | – | Similar proportions of satisfactory response | – | Reduced in TFC/MTX | 2b |
| Winthrop64 Part B    | 2016 | Cohort | 92 RA-TFC cont. 91 RA-TFC stop | No difference | – | No | 2b |
| Alten83              | 2016 | Cohort | 184 RA ABT+MTX | – | Adequate response | – | See column immunogenicity | 2b |
| Luque Ramos203       | 2016 | Cohort (retrospective database) | 111482 RA 555410 HCs | Trend towards higher hospital admittance rates for pneumonia in areas with lower influenza and pneumococcal vaccine uptake | – | – | 5 |
| Kogure74             | 2014 | Cohort | 57 RA: 9 biologics 34 MTX 8 TAC 10 GC 14 SASP | – | Seroprotection: H1N1 63%, H3N2 81%, influenza B 26% | No change in disease activity, no AE Reduced on biologics | – 2b 4 |
| Milanetti41 Both seasonal and pandemic | 2014 | Cohort | 30 RA 13 HCs | – | No difference | Milder AE in patients No changes in disease activity | No effect of anti-TNF or ABT | 2b 4 |
| Kobashigawa36        | 2013 | Cohort (prospective) | 17735 RA in 4 seasons (12.2%–38.7% vacc) | Vaccination associated with reduced self-reported risk of influenza | – | – | No 2b |
| Milanovic37          | 2013 | Cohort | 19 SLE-vacc. 11 SLE 15 RA-vacc. 22 RA 13 SjS-vacc. 19 SjS | Lower incidence of influenza and bact. Complications among vaccinated pts | Sign. difference in GMT between vacc./unvacc. SLE, but not in RA and SjS | No changes in disease activity | No 4 2b 4 |
| Tsuru81              | 2013 | Cohort | 36 TCZ (28 RA/10 CD) 39 RA anti-TNF/DMARD | – | No difference | – | No 2b 4 |
| Mori73               | 2012 | Cohort | 62 RA-TCZ 65 RA-MTX 49 RA-TCZ +MTX 18 RA-DC | Adequate immune response, but lower on MTX | No systemic AE No flares | Reduced on MTX | 2b 4 |

Continued
| First author +ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff./imm. | LoE |
|---------------------|------|--------------|-----------|----------|----------------|--------|----------------------------|-----|
| **Kogure**<sup>12</sup> | 2012 | Cohort | RA treated with Japanese Kampo medicine: 24 RA+MTX 16 RA-DC | – | No difference Low response in general | No AE No influence on disease activity | No influence of MTX | – 4 4 |
| **Arad**<sup>28</sup> | 2011 | Cohort | 29 RA-RTX (16<5 mo, 13<5 mo) 17 RA-DC 16 HCs | – | Humoral immunity: reduced in RA-RTX Similar percentage of influenza-specific IFN-γ producing CD4+ cells in RA groups | No change in disease activity | Humoral immunity: Reduced on RTX Cellular immunity: No | – 2b 4 |
| **Kobie**<sup>40</sup> | 2011 | Cohort | 61 RA-anti-TNF 70 RA-MTX 33 RA-DC 97 HCs | – | Redundant in RA-anti-TNF | – | Reduced on anti-TNF | – 2b – |
| **Rehnberg**<sup>37<sup>2</sup> | 2010 | Cohort | 11 RA 6 mo post-RTX 8 RA 6 d pre-RTX 10 RA-DC | – | Lower frequency influenza-specific B cells in peripheral blood in post-RTX group 6 d after vacc. Lower humoral response 21 d after vacc. in post-RTX group | – | Reduced on RTX | – 4 – |
| **Salemi**<sup>71</sup> | 2010 | Cohort | 22 RA-anti-TNF 10 HCs | – | Lower in RA | No SAE No difference in AE No change in disease activity | ANA appearance/increase similar RA and HCs | – – 2b 4 |
| **Huang**<sup>47</sup> | 2016 | Meta-analysis | 15 studies in SLE (also including pts<18 years) | – | Reduced immunogenicity SLE compared with HCs for H1N1 and B, but not for H3N2 Respective SP: 66%, 64%, 60% Lower response with non-adjuvanted vaccine | Disease activity not influenced by vaccination No difference in AE between SLE and HCs | GC, AZA or IS in general: reduced immunogenicity HCs:Q: No difference | – 2a 2a |
| **Pugès**<sup>16</sup> | 2016 | Meta-analysis | 17 studies in SLE | – | Immunogenicity depends on viral strains: reduced against A and preserved for B | No influence on disease activity | – | – 2a 2a |
| **Liao**<sup>46</sup> | 2016 | Meta-analysis | 18 studies in SLE | – | Reduced in SLE for H1N1 and H3N2, but not for B Respective SP: 68%, 76%, 66% All side effects mild and transient Similar rate of AE in SLE and HCs 2 severe flares | – | – 2a 2a |

**Table 4** Continued
| First author + ref. | Year  | Study design | No. cases | Efficacy                                                                 | Immunogenicity                                                                 | Safety                                                                 | Influence of IS on eff./imm. | LoE | Eff. | Imm. | Saf. |
|---------------------|-------|--------------|-----------|--------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------|-----|------|------|------|
| Chang et al.        | 2016  | Cohort       | 1765 SLE-vacc. 8360 SLE non-vacc. | Reduction of complications of influenza in vaccinated patients | --                                                                          | --                                                                      | --                          | 2b  | --   | --   | --   |
| Launay et al.       | 2013  | Cohort       | 27 SLE    | Percentage of responders at day 30 are 55.5%, 18.5% and 55.5%, for H1N1, H3N2 and influenza B, respectively | Increase in rheumatoid factor levels, after vacc. No flares. | --                                                                     | 4                           | 4   | --   | --   | --   |
| Vista et al.        | 2012  | Cohort       | 101 SLE 101 HCs | Similar proportion new onset antocardiolipin antibodies | --                                                                          | --                                                                      | --                          | 4   | --   | --   | --   |
| Crowe et al.        | 2011  | Cohort       | 72 SLE 72 HCs | No difference. More high responses in African-American subjects. | 19.4%/26.4% flare 6/12 weeks postvacc. More low responders with flare at 6 weeks. | Reduced on steroids          | --                          | 4   | 4    |     |     |
| Wallin et al.       | 2009  | Cohort       | 47 SLE: 23 GC 8 MTX 9 AZA 27 HCs | No difference in seroprotection | Overall stable disease Reduced on steroids | 2b                         | 4                           |     |     |     |     |
| Jaeger et al.       | 2017  | Cohort       | 107 injections influenza vaccine in 55 CAPS | -- | AE in 7% of injections Fever in 2% No SAE | --                          | --                          | 4   | --   | --   | --   |
| Caso et al.         | 2016  | Cohort       | 25 PsA-vacc. 25-PsA DC | -- | Higher tender joint count and ESR after 1 month, more episodes mild symptoms in PsA-vacc. | --                          | --                          | 4   | --   | --   | --   |
| Jeffs et al.        | 2015  | Cohort       | 24 AAV-vacc. 67 AAV non vacc. 53 HCs | Adequate, but lower response in AAV | No SAE Significant increase in local AE following vaccination only in HCs No change in disease activity | --                          | --                          | 2b  | 2b   |     |     |
| Polacheck et al.    | 2015  | Cohort       | 63 PsA 4 Pso 30 HCs | No difference | Increased CRP in patients 4–6 weeks postvacc. | No                          | --                          | 2b  | 2b   |     |     |
| Litinsky et al.     | 2012  | Cohort       | 26 SSc 16 HCs | Increased in SSc for H1N1 No difference for H3N2 and influenza B | Overall stable disease Increased on combination iloprost and calcium channel blockers for H1N1 and influenza B | --                       | 2b                         | 4                           |     |     |     |     |
### Table 4 Continued

| First author | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff./imm. | LoE | Eff. | Imm. | Saf. |
|--------------|------|--------------|-----------|----------|----------------|--------|--------------------------------|-----|------|------|------|
| Kostianovsky | 2012 | Cohort       | 74 systemic vasculitis | –        | No difference | 19 flares | No                               | –   | 4    | 4    |      |

The table is structured as follows: First studies in RA, then SLE followed by other autoimmune inflammatory rheumatic diseases (AIIRD). Within this organisation, articles are clustered in study design (meta-analyses, RCT, cohort studies, case series) and presented in order of publication year: AAV, ANCA-associated vasculitis; ABP, abatacept; ANA, antinuclear antibodies; A2A, azathioprine; bact., bacterial; CAPS, cryopyrin associated periodic syndrome; CD, Castleman’s disease; CTR, randomised controlled trial; d., days; DC, disease control; D-MARD, disease-modifying antirheumatic drug; eff., efficacy; ESR, erythrocyte sedimentation rate; GC, glucocorticoids; GMT, geometrical mean titre; HC, healthy controls; HQQ, hydroxychloroquine; IFN, interferon; imm., immunogenicity; IS, immunosuppressives; LoE, level of evidence; mo., months; MTX, methotrexate; No., number; NR, not reported; PCI, placebo; PIA, psoriatic arthritis; Pts, patients; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; RR, relative risk; RTX, rituximab; SAE, serious adverse events; saf., safety; SASP, salazosulfapyridine; SC, seroconversion; sign., significant; SJ, Sjögren’s syndrome; SLE, systemic lupus erythematosus; SP, seroprotection; SSc, systemic sclerosis; TAC, tacrolimus; TCZ, tocilizumab; TFC, tofacitinib; TNF, tumor necrosis factor; vacc., vaccinated; yrs, years.

To date, 91 pneumococcal serotypes have been identified, 30 of them being responsible for up to 90% of all infections. Although the pneumococcal polysaccharide vaccine that includes 23 serotypes (PPSV23) was found to protect against invasive pneumococcal infections in the general population, it did not generate immunity in children younger than 2 years of age. Therefore, in 2000 a pneumococcal conjugate vaccine comprising seven antigens (PCV7) was developed and subsequently expanded to 13 serotypes (PCV13), which was licensed in 2010 based on immunogenicity outcome studies. Although the pneumococcal polysaccharide vaccine is effective at preventing invasive pneumococcal infections, the majority of studies have been conducted in older adults. However, recent studies have shown that the pneumococcal vaccine is also effective in preventing pneumococcal infections in young children. The updated EULAR recommendation should be strongly considered for the majority of patients with AIIRD.3

The effect of glucocorticoids on the immune response, to influenza vaccine, has mainly been studied in combination with other immunosuppressive agents. The antibody response is generally adequate in patients who were on glucocorticoids at the time of influenza vaccination, although some studies did find a mildly reduced response.21–23, 42, 47

### Pneumococcal vaccination

To ensure adequate coverage against pneumococcal infections, vaccination is recommended for all patients with AIIRD, including those who are receiving immunosuppressive therapy. The PCV13 vaccine is recommended for all children aged 2 years and older, and the PPSV23 vaccine is recommended for adults aged 65 years and older. The PCV13 vaccine is also recommended for all children aged 2 years and older who are at high risk of pneumococcal disease, including patients with AIIRD. However, the PCV13 vaccine is less immunogenic in patients with AIIRD compared to healthy controls.

### Summary and clinical implications

Seasonal and pandemic influenza vaccination is associated with a reduced incidence of bacterial complications. In patients with RA and SLE, influenza vaccination has been shown to improve clinical outcomes. The addition of immunosuppressive agents to the vaccine, such as tocilizumab, has been shown to be safe and effective in preventing influenza complications. However, the effect of immunosuppressive therapy on the immune response to influenza vaccination has not been studied in detail.

Only one study investigated the influence of tocilizumab on influenza vaccination in AIIRD. Tocilizumab was associated with a lower response to the vaccine, but a combination of tocilizumab and methotrexate was associated with a higher response. Further studies are needed to determine the optimal strategy for vaccination in patients with AIIRD.
| First author + ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff./ imm. | LoE | Eff. | Imm. | Saf. |
|---------------------|------|--------------|-----------|----------|----------------|--------|------------------------------|-----|------|------|------|
| Milanetti* | 2014 | Cohort | 30 RA 13 HC | – | No difference | More mild AE in patients | No effect of anti-TNF or ABA | – | 2b | 4 |
| Kapetanovic* | 2014 | Cohort | 50 RA-MTX 38 RA-anti-TNF 53 RA-anti-TNF+MTX 5 RA-ABA-10 RA-RTX 2 RA TCZ 41 SpA-anti-TNF 51 SpA-anti-TNF+MTX Two doses in 58% | – | Reduced in RA-RTX Increased in SpA-anti-TNF Increased after two doses, except for RA-MTX and RA-RTX | One pneumonia 8.2% of patients reported that vaccination influenced their inflammatory disease | Reduced on RTX and ABA (only five pts) | – | 2b | 4 |
| Ribeiro* | 2013 | Cohort | 11 RA-ABA 33 RA-MTX DC 55 HC | – | Reduced in RA-ABA | No difference AE | Reduced on ABA | – | 2b | 4 |
| Adler* | 2012 | Cohort | 47 RA 59 SpA 15 vasculitis 28 CTD 40 HC | – | Reduced in patients (but not in SpA and CTD) | No difference in AE. Increased disease activity in 32 patients | Reduced on ABA, RTX (n=8) and MTX 2 responders in RTX group: 1 and 3 mo after RTX | – | 2b | 4 |
| França* | 2012 | Cohort | 41 RA-anti-TNF 79 SpA-anti-TNF 41 RA-DC 75 SpA-DC 117 HC | – | Reduced in SpA-anti-TNF but not for etanercept | More mild systemic AE in patients on anti-TNF | Reduced on MTX (RA), Reduced on anti-TNF (SpA) except etanercept | – | 2b | 4 |
| Iwamoto* | 2012 | Cohort | 89 RA 14 HC | – | Reduced (non-significant) in RA Seroprotection 55.1% | 1 facial palsy | Lower (non-significant) on biologics | – | 2b | 5 |
| Saad* | 2011 | Cohort | 1668 AIIRD* 234 HC | – | Reduced in AIIRD versus HC Reduced in SLE and RA | Overall stable disease | No | – | 2b | 4 |
| Gabay* | 2011 | Cohort | 82 RA 45 SpA 46 other AIIRD 138 HC | – | Reduced in patients No difference after two doses in patients (seroprotection after 1 and 2 doses 75% and 85%, respectively) | Overall stable disease | Reduced on DMARDs and within 3 mo. after B cell depletion | – | 2b | 4 |
| Miraglia* | 2011 | Cohort | 1152 Immunocompromised: 260 RA 83 JIA | – | Seroprotection in 61.5% of patients with RA and in 85.5% of patients with JIA | Mild systemic AE in more than 20% of RA and JIA | – | – | 2b | 4 |
| Elkayam* | 2011 | Cohort | 41 RA 21 SLE 17 Pa 15 AS 25 HC | – | Reduced in patients with RA/PaA Seroprotection in 60%–76% of patients | Overall stable disease | Reduced on leflunomide and infliximab | – | 2b | 4 |
| Ribeiro* | 2011 | Cohort | 340 RA 234 HC | – | Reduced in RA No influence of disease activity | More local AE in HC. More mild systemic AE in RA | Reduced on MTX | – | 2b | 2b |
| Müller* | 2013 | Case series | 16 RA+SjS | – | SC in B cell depleted: 22%, non-depleted: 57% | More influenza-like symptoms in B cell depleted patients | Low response with RTX | – | 4 | 5 |

* Adj. (MF59)

Continued
| First author + ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence of IS on eff./ imm. | LoE |
|---------------------|------|--------------|-----------|----------|---------------|--------|-------------------------------|-----|
| Borba et al.        | 2012 | Cohort      | 555 SLE 170 HC | –       | Reduced in SLE with therapy (except for antimalarials) No difference in HC and SLE without therapy | Overall stable disease | Reduced for steroids and IS Restored when using concomitant antimalarials | 2b 2b |
| Kostianovsky et al. | 2012 | Cohort      | 74 systemic vasculitis 32 SSc 29 SLE 23 SS 28 other AIIRD | –       | No difference | 19 flares | No | – 4 4 |
| Lu et al.           | 2011 | Cohort      | 21 SLE 15 HC | –       | No difference | Changes in autoantibody levels Overall stable clinical disease activity one flare | No | – 2b 4 |
| Urowitz et al.      | 2011 | Cohort      | 103 SLE: 51 adj. 52 non-adj. | –       | No difference | Overall stable disease | – | – 2b |
| Mathian et al.      | 2011 | Cohort      | 111 SLE | –       | Increased after booster vaccination (seroprotection after 1 and 2 doses 67% and 80%, respectively) No severe AE Overall stable disease Reduced on IS | – 2b 4 |
| Brauner et al.      | 2017 | Cohort      | 14 SJ 18 HC | –       | Higher levels of influenza-specific IgG in patients, and higher avidity Antibody titres to non-influenza (incl autoantigens Ro/SSA and La/SSB) antigen increased in patients, but not in HC. | – | – 4 4 |
| Sampaio-Barros et al.| 2017 | Cohort      | 92 SSc 92 HC | –       | Higher GMT SSc Comparable SP and SC No difference in AE No SAE | No | – 2b 4 |
| De Medeiros et al.  | 2014 | Cohort      | 45 PAPS 33 HC | –       | No difference | No change in overall frequencies of autoantibodies | – | – 2b |
| Miossi et al.       | 2013 | Cohort      | 69 MCTD 69 HC | –       | No difference | Overall stable disease | No | – 2b 4 |
| Shinjo et al.       | 2012 | Cohort      | 37 DM +21 PM 116 HC | – | No difference | No difference | No Overall stable disease | – 2b 4 |

The table is structured as follows: First studies in RA, then systemic lupus erythematosus (SLE) followed by other autoimmune inflammatory rheumatic diseases (AIIRD). Within this organisation, presented in order of publication year.

*Group consisted of patients with SLE (n=572), RA (n=443), psoriatic arthritis (n=101), anklylosing spondylitis (n=152), Behçet’s disease (n=85), dermatomyositis (n=45), systemic sclerosis (n=127), mixed connective tissue disease (n=69), primary antiphospholipid syndrome (n=2), primary Sjögren’s syndrome (n=38), Takayasu’s arteritis (n=26), polymyositis (n=28), granulomatosis with polyangiitis (n=26).

†Group consisted of patients with cancer (n=318), RA (n=263), HIV infection (n=256), kidney transplant recipients (n=85), juvenile idiopathic arthritis (n=83) and elderly persons (n=149).

ABA, abatacept; adj., adjuvant; AS, anklyosing spondylitis; AT, atypical test; DC, disease control; DM, dermatomyositis; DMARD, disease-modifying antirheumatic drug; eff., efficacy; GMT, geometric mean titre; HC, healthy controls; imm, immunogenicity; IS, immunosuppressives; JIA, juvenile idiopathic arthritis; LoE, level of evidence; (Mc)TD, (mixed) connective tissue disease; mo., months; MTX, methotrexate; No., number; PAPS, primary antiphospholipid syndrome; PM, polymyositis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; ref., reference; RTX, rituximab; (S)AE, (serious) adverse event(s); saf., safety; SC, seroconversion; SS, Sjögren’s syndrome; SP, seroprotection; SpA, spondyloarthropathy; SSc, systemic sclerosis; TCZ, tocilizumab; TNF, tumor necrosis factor.
Table 6  Influence of disease-modifying antirheumatic drugs on influenza and pneumococcal vaccine efficacy and immunogenicity

| Drug Type               | Efficacy       | Immunogenicity                          | LoE Immunogenicity |
|-------------------------|----------------|-----------------------------------------|--------------------|
|                         |                | Influenza                               | Pneumococcal       |
| MTX                     | No data        | Adequate for influenza/reduced for pneumococcal | 2a 2b              |
| Other cs-DMARD          | No data        | Only for HCQ Adequate                   | 4 4                |
| Anti-TNFα               | No data        | Adequate                                 | 2a 2b              |
| B cell depletion        | No data        | Reduced                                  | 2a 2b              |
| Belimumab               | No data        | Pneumococcal: preserved                  | – 2b               |
| Tocilizumab             | No data        | Preserved                                | 2b 2b              |
| Abatacept               | No data        | Controversial                             | 4 4                |
| Tofacitinib             | No data        | Adequate for influenza, reduced for pneumococcal | 2b 2b              |
| Glucocorticoids (±other IS) | No data        | Adequate for influenza, mildly reduced in high doses GC for pneumococcal | 4 2b              |

cs-DMARD, conventional synthetic disease-modifying antirheumatic drugs; GC, glucocorticoids; HCQ, hydroxychloroquine; IS, immunosuppressives; LoE, level of evidence; MTX, methotrexate; TNF, tumour necrosis factor.

non-bacteraemic community-acquired pneumonia as well as vaccine-type invasive disease.89

Up to the previous recommendations, 15 studies addressed the issue of immunogenicity and safety of PCV13 and PPSV23 in patients with AIIRD: 7 studies in RA,8 90-95  8 in SLE,95-102  2 in patients with spondyloarthritis (SpA)91 103 and 1 in pSS.104 Adequate as well as reduced immunogenic responses compared with controls were reported in these studies. Treatment with rituximab, TNFα blockers and MTX seemed to impair the humoral response to the pneumococcal vaccine.16 90 92 93

From the previous recommendations and up to August 2018, 34 studies53 76 81 83 84 105–133 and two meta-analyses45 77 have been published on the efficacy, immunogenicity and safety of PPSV23 and the conjugated vaccines PCV7 and PCV13, including evaluation of a combined strategy (tables 7 and 8).106 128 133

Regarding efficacy of pneumococcal vaccination in AIIRD, a randomised double-blind trial on the clinical efficacy of PPSV23 in preventing pneumonia in patients with RA did not demonstrate an increased efficacy of the vaccine over placebo, emphasising the need for a more efficacious vaccine.120 In contrast, a retrospective study on the long-term effect of PPSV23 in 180 patients with RA treated with MTX showed a relative risk of 9.7 to develop pneumonia among non-vaccinated patients.121 Vaccination with PCV7 tended to reduce the risk of pneumococcal infections in patients with RA and SpA.122 In this cohort, a direct correlation was shown between the postvaccination levels of antipneumococcal antibodies and the risk of pneumococcal infections: more robust antibody responses after vaccination with PCV7 were associated with lower risk of serious pneumococcal infections.123 The humoral immunogenicity and safety of PPSV23 were demonstrated in RA,76 81 109 112 113 119 124 SLE,116 125 134 and, to a limited extent, in SpA and other rheumatic diseases.115 The long-term immunogenicity of PPSV23 was evaluated in two studies in patients with RA, treated with MTX121 and biologics.120 Both have shown a long-term duration of protective antibodies, up to 7 years.

Humoral immunogenicity of PCV7 is similar to that of PPSV23,111 but was shown to decrease after 1.5 years.127 A randomised controlled study in patients with SLE aiming at evaluating the immunogenicity of the combination of PCV7 and PPSV23 in comparison with PPSV23, showed an adequate and similar response in the two groups.128 The immunogenicity of PCV7 is preserved in patients with ANCA-associated vasculitis on remission.105

The immunogenicity of PCV13 has been evaluated in small groups of patients with RA,118 129 SLE114 and pSS.131 It induced an adequate humoral response.

Three studies evaluated the prime-boost strategy. In SLE, the combination of PCV7 and PPSV23 was not more immunogenic than PPSV23 alone.128 Another randomised controlled study evaluated the serological response to PCV13 followed by PPSV23 after 16–24 weeks in patients with RA, with one of the arms including two doses of PCV13. This study demonstrated an adequate response in patients with RA (87% and 94% on biological disease-modifying antirheumatic drugs (DMARDs) and conventional synthetic DMARDs, respectively), without additional effect of two PCV13 injections.106 An additional study has questioned the long-term effect of the prime boosting strategy using PCV13 and PPSV23, showing reduced levels of functional antibodies 2 years after vaccination.103

No safety issues following pneumococcal vaccination in most of the AIIRDs were reported, independent of
| First author + ref. | Year | Study design | No. cases | No. ST | Efficacy | Immunogenicity | Safety | LoE | Eff. | Imm. | Saf. |
|---------------------|------|--------------|-----------|--------|----------|----------------|--------|-----|------|------|------|
| Izumi120            | 2017 | RCT         | 464 RA-vaccinated 436 RA-placebo | NA     | Similar efficacy in vaccinated versus placebo | –         | No safety issue | 1b-2b | –   | –    |
| Kivitz131           | 2014 | RCT         | 110 RA-Certolizumab (68%+MTX)114 RA-Placebo (68%+MTX) | 6      | –         | No difference between certolizumab and placebo | –         | –   | 1b-2b | –    |
| Hesselstrand131     | 2018 | Cohort      | 44 SSC: 31 PPSV23 13 PCV13 49 HC | 2      | –         | Lower response in patients treated with DMARDs | No safety issue | 2b  | 4    |
| Jaeger133           | 2017 | Cohort      | 16 patients with CAPS | NA     | –         | –         | Significant side effects | –   | 4    |
| Chatham125          | 2017 | Cohort      | 34 SLE PPSV23 4 weeks before, and 45 SLE 24 weeks after belimumab | 23     | –         | Adequate response, not affected by belimumab | No safety issue | 2b  | 4    |
| Broyde134           | 2016 | Cohort (retrospective) | 88 RA and SpA vaccinated 42 RA and SpA non-vaccinated | NA     | –         | Preserved immunogenicity after 7 years | –         | –   | 2b   |
| Winthrop84 Part A   | 2016 | Cohort      | 102 RA-Tofacitinib 98 RA-Placebo | 12     | –         | Reduced response in tofacitinib-treated patients | –         | –   | 2b   |
| Winthrop84 Part B   | 2016 | Cohort      | 92 RA-Cont Tofacitinib 91 RA-Stop Tofacitinib | 12     | –         | No difference between groups | –         | –   | 2b   |
| Alten83             | 2016 | Cohort      | 125 RA ABA+MTX | 5      | –         | Adequate response | No safety issue | 2b   | 4    |
| Rezende116          | 2016 | Cohort      | 54 SLE | 7      | –         | Poor immunogenicity | –         | –   | 2b   |
| Migita109           | 2015 | Cohort      | 35 RA-DMARDs 55 RA-MTX 21 RA-ABA +MTX | 2      | –         | Reduced response in abatacept-treated patients | No safety issue | 2b  | 4    |
| Migita124           | 2015 | Cohort      | 35 RA-DMARDs 55 RA-MTX 24 RA-Golimumab +MTX | 2      | –         | Reduced response in golimumab-treated patients | No safety issue | 2b  | 4    |
| Migita119           | 2015 | Cohort      | 35 RA-DMARDs 55 RA-MTX 29 RA-Tacrolimus 14 RA-Tacrolimus +MTX | 2      | –         | Higher response in tacrolimus-treated patients | No safety issue | 2b  | 4    |
| Bingham112          | 2015 | Cohort      | 27 RA-MTX 54 RA-MTX +TCZ | 12     | –         | Similar response in patients treated with MTX or MTX +TCZ | No safety issue | 2b  | 4    |
| Fischer115          | 2015 | Cohort      | 57 vaccinated/122 non-vaccinated RA,SpA, vasc.,CTD | NR     | –         | Adequate response | –         | 4   | –    |
| Tsuru81             | 2014 | Cohort      | 21 RA-TCZ | 12     | –         | All TCZ-treated patients responded | –         | 2b  | –    |
Influence of immunomodulating agents
Humoral immunogenicity of PPSV23 has been shown to be reduced by MTX, \textsuperscript{119} abatacept, \textsuperscript{109} golimumab, \textsuperscript{241} tocilizumab, \textsuperscript{94} and rituximab, \textsuperscript{96} but not to be affected by certolizumab \textsuperscript{76} and belimumab. \textsuperscript{125} Immunogenicity following PCV7 vaccination is reduced by the use of MTX, \textsuperscript{110} abatacept and rituximab, \textsuperscript{108} but not by TNFα blockers. \textsuperscript{110} Additionally, the humoral response of PCV13 is reduced under MTX. \textsuperscript{118} A randomised controlled study in patients with RA that evaluated the serological response to PCV13 followed by PPSV23 after 16–24 weeks, showed a significantly decreased response in patients treated with rituximab. The prime-boost strategy with PCV13 did not improve the response \textsuperscript{106} (see table \textsuperscript{6} for summary).

Summary and clinical implications
Stepwise pneumococcal vaccination, according to the prime-boost strategy (PCV13 followed by PPSV23, with an interval of at least 8 weeks between the two vaccinations) is currently recommended by the Centers for Disease Control and Prevention (CDC) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) for young children, adults above 65 years of age and patients at risk for pneumococcal disease. \textsuperscript{135} This is mainly based on expert opinion, although studies conducted in the general population \textsuperscript{136-137} and in patients with HIV \textsuperscript{138} did show an augmented immunogenic response following combined vaccination.

Pneumococcal vaccination should be strongly considered for the majority of patients with AIIRD for the following considerations: (1) The increased risk of non-invasive and invasive pneumococcal disease in patients with AIIRD. \textsuperscript{1} (2) Good efficacy, immunogenicity and a favourable safety profile of pneumococcal vaccines (with the exception of patients with CAPS). (3) In line with the present recommendations of the CDC \textsuperscript{87, 139} and the ESCMID. \textsuperscript{135} Given the insufficient evidence for the efficacy of the combination of PCV13 and PPSC23, the choice and sequence of pneumococcal vaccination should be in concordance with local guidelines.

Hepatitis A vaccination
Efficacy—immunogenicity—safety
Hepatitis A virus (HAV) vaccine, an inactivated vaccine, is very efficacious in preventing hepatitis A. \textsuperscript{140, 141} There are however no studies on the efficacy of HAV vaccination in patients with AIIRD. All three studies on immunogenicity HAV vaccination in patients with AIIRD have

| No. | ST | Efficacy | Immunogenicity | Safety |
|-----|----|----------|----------------|--------|
| 2   | -  | 4        | Preserved immunogenicity after 7 years | -      |
| NA  | -  | -        | Reduced in patients treated with RTX | -      |

*Table 7 Continued*

- Coulson \textsuperscript{121}
- Rehnberg \textsuperscript{97}
- ABA, abatacept; PCPS, cryopyrin-associated periodic syndrome; cont., continued; CTD, connective tissue disease; DC, dermatomyositis; ECMO, extracorporeal membrane oxygenation; HCV, hepatitis C virus; HLA, human leukocyte antigen; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IQR, interquartile range; IV, intravenous; IVIG, intravenous immunoglobulin; LFT, liver function test; MAB, monoclonal antibody; MDARDs, non-biological DMARDs; NDS, non-biological DMARDs; RCT, randomised controlled trial; RTX, rituximab; SC, subcutaneous; SpA, spondyloarthropathy; SSc, systemic sclerosis; ST, serotypes; TCZ, tocilizumab; vasc., vasculitis.

*Table 7 Continued*
Table 8 Immunogenicity and safety of 7-valent and 13-valent pneumococcal conjugate vaccine (PCV7 and PCV13), including prime boosting with 23-valent pneumococcal polysaccharide vaccine (PPSV23), in patients with AIIRD (October 2009–August 2018)

| First author + ref. | Year | Study design | No. cases | Strategy | No. ST | Immunogenicity | Safety | LoE | Imm. | Saf. |
|---------------------|------|--------------|-----------|----------|--------|----------------|--------|-----|------|------|
| Grabar128           | 2017 | RCT         | 46       | SLE: 27 placebo +PPSV23 19 PCV7 +PPSV23 | NA    | Adequate immunogenicity No differences between groups | No safety issue | 1b | 4    |
| David Morgan105     | 2016 | Cohort      | 92       | AAV     | NA    | Preserved immunogenicity in patients on remission | -- | 2b | --  |
| Nagel123            | 2015 | Cohort      | 248      | RA 249 SpA | NA    | Good correlation between levels of immunogenicity and incidence of pneumonia | -- | 2b | --  |
| Kapetanovic108      | 2013 | Cohort      | 173      | RA (TCZ, RTX, ABA, MTX) 86 SpA controls | NA    | Reduced response in patients treated with ABA and RTX | No safety issue | 2b | 4    |
| Kapetanovic127      | 2013 | Cohort      | 163      | RA 139 SpA | NA    | Reduced immunogenicity after 1.5 y | -- | 2b | --  |
| Kapetanovic110      | 2011 | Cohort      | 253      | RA 252 SpA (MTX, anti-TNF) | NA    | Reduced response in pts treated with MTX | No safety issue | 2b | 4    |
| Kapetanovic111      | 2011 | Cohort      | 201      | RA (PCV7) 201 RA (PPSV23) | NA    | Similar immunogenicity for PCV7 and PPSV23 | No safety issue | 2b | 4    |
| Nguyen106           | 2017 | RCT         | 98       | RA 63 bDMARD 35 csDMARD-DC | PCV 13+PPSV23 PCV13+PPSV23 PCV13+PPSV23 | Adequate and similar response in the three arms | No safety issue | 2b | 4    |
| Bahuaud133          | 2018 | Cohort      | 23       | RA | PCV13 +PPSV23 | Adequate short-term response Functional antibodies decreased after 2 years | -- | 2b | --  |
| Kapetanovic138      | 2017 | Cohort      | 10       | RA-MTX 10 RA-DC | PCV13 | Reduced response in MTX-treated patients | -- | 4  | --  |
| Nived117            | 2017 | Cohort      | 49       | vasculitis 49 HC | PCV13 | Adequate response, similar in both groups | No safety issue | 2b | 4    |
| Nagel114            | 2017 | Cohort      | 47       | SLE 21 HC | PCV13 | Decreased response in IS-treated patients with SLE, preserved under HCQ and belimumab | No safety issue | 2b | 4    |
| Rakoczi129          | 2016 | Cohort      | 22       | RA 24 OA | PCV13 | Adequate immunogenicity, but lower in RA | No safety issue | 2b | 4    |
| Groh132             | 2017 | Case series | 19      | AAV 9 induction 10 maintenance | PCV13/PCV 7±PPSV23 | Decreased response on induction, preserved on maintenance therapy | -- | 4  | --  |

AAV, ANCA-associated vasculitis; ABA, abatacept; ANCA, antineutrophil cytoplasmic antibodies; bDMARD, biological disease-modifying antirheumatic drug; (cs)DMARD, (conventional synthetic) DMARD; DC, disease control; HC, healthy controls; HCQ, hydroxychloroquine; imm., immunogenicity; IS, immunosuppressives; LoE, level of evidence; MTX, methotrexate; No., number; NR, not reported; OA, osteoarthritis; pts, patients; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; RTX, rituximab; saf., safety; SLE, systemic lupus erythematosus; SpA, spondyloarthritis; ST, serotypes; TCZ, tocilizumab; TNF, tumor necrosis factor; y, years.
been published after the 2011 version EULAR recommendations and SLR142 (table 9).

In healthy persons, the HAV vaccine is highly immunogenic, resulting in seroprotection in ≥95% only 1 month after the first vaccine dose.143 144 In patients with RA, it has been shown to be less immunogenic. The percentage of seroprotected patients with RA after 1 month varied between 10%145 and 60%–68%146 in two studies that used different methods. A three-dose schedule (0, 1 and 6 months or 0 (double dose) and 6 months) resulted in 99% seroconversion in patients with RA after 12 months.146 A double dose of vaccine at baseline did not result in an improved seroconversion rate after 1 month, compared with the usual dose (68% vs 60%).146

In terms of safety, there are no data on the influence of vaccination on activity of the underlying AIIRD. Adverse events were generally mild, and reported in up to 17% of patients.145 146 Askling et al reported one case of meningoencephalitis which occurred in a patient with an RA 2.5 weeks after the second dose of HAV vaccine.145

### Influence of immunomodulating agents

Using a cut-off for seroprotection of anti-HAV ≥10 mIU/mL instead of 20 mIU/ml, significantly more patients with RA using only an anti-TNFα agent (73%, n=15) reached seroprotection than those using a combination of anti-TNF and MTX (15%, n=21) or MTX alone (6%, n=17).145 In a study of 173 immunosuppressive-treated patients (31 anti-TNF, 123 classic DMARD and 19 other), the use of anti-TNF was associated with lower seroprotection rates in a multivariate logistic regression analysis (see table 9).147

### Summary and clinical implications

Since a single dose of HAV vaccine does not seem to afford sufficient protection in a substantial percentage of patients with AIIRD, it is recommended to administer a second dose of vaccine 6 months after the first and to determine postvaccination antibody titres. If this is not possible, as in the case of a last-minute traveller, it should be borne in mind that a patient with AIIRD may not be protected after a single dose of HAV vaccine. Passive immunisation for the specific journey may be considered.

### Hepatitis B vaccination

#### Efficacy—immunogenicity—safety

The incidence of hepatitis B virus (HBV) infections has markedly decreased in countries where HBV vaccination is routinely implemented.148 Although no antibody level gives complete protection against transient infection, there is a clear association between antibody level and risk of HBV infection.149 In general, a level of antihepatitis B surface antigen ≥10 mIU/ml is considered protective.
Up to the previous version of recommendations, a total of four studies reported on the immunogenicity of HBV vaccination in patients with RA, \(^{156}\) SLE, \(^{157}\) AS \(^{152}\) and Behçet’s disease. \(^{158}\) One additional study in patients with RA had been published since then (online supplementary table S1). \(^{154}\)

This recent study, including 46 patients with RA and 9 HCs, reported a significantly lower percentage of patients versus HCs reaching seroprotective antibody levels (64% in patients vs 100% in HCs). \(^{154}\) Another controlled study from 2005, with 13 patients with Behçet’s disease and 15 HCs reported no difference in immunogenicity of the HBV vaccine. \(^{153}\) A response to the vaccine was demonstrated in all remaining studies on HBV vaccination in patients with AIIRD that did not include a control group \(^{150}-^{152}\) (online supplementary table S1).

The HBV vaccine did not lead to changes in overall disease activity in patients with RA and Behçet’s disease. \(^{150}^{153}^{154}\)

**Influence of immunomodulating agents**

A severely hampered antibody response to HBV vaccination was noted in patients with AS treated with TNF-blocking agents. \(^{152}\)

**Summary and clinical implications**

HBV vaccine should be administered to patients with AIIRD at risk of infection, for example, medical personnel, patients having an infected family member, intravenous drug users, men who have sex with men, and patients travelling to or residents from endemic countries. It is advised to determine vaccination response. For non-responders several strategies are available to try to reach seroprotection. A booster vaccination or passive immunisation should be considered for an unvaccinated patient or a patient with insufficient response exposed to HBV. See recommendations of the CDC via [https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf](https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hepb.pdf).

**Tetanus toxoid vaccination**

**Efficacy—immunogenicity—safety**

The efficacy of tetanus toxoid vaccination in the prevention of tetanus has never been studied in a vaccine trial. The incidence of tetanus has been shown to decrease dramatically in vaccinated populations, \(^{155}^{156}\) although this was not specified for the AIIRD population. The protective antibody level for tetanus is generally considered to be ≥0.1 IU/mL. Tetanus is extremely rare in fully immunised adults who received their last dose of vaccine within the preceding 10 years.

Reports on immunogenicity of tetanus toxoid vaccination in patients with RA showed satisfactory antibody responses. \(^{9}^{112}^{157}\) Most studies in patients with SLE reported adequate response rates. \(^{102}^{157-159}\) One small study from 1980 including nine patients with SLE and nine HCs showed a diminished response in the patients with SLE, with a blunted response in three of them. \(^{160}\)

Most studies did not report on safety of tetanus toxoid vaccination. One randomised controlled trial (RCT) showed a higher incidence of mild/moderate adverse events after combined tetanus toxoid and pneumococcal vaccination in patients with RA on MTX who recently started the use of tocilizumab, compared with patients with RA on MTX only (online supplementary table S2). \(^{112}\)

**Herpes zoster vaccination**

**Efficacy—immunogenicity—safety**

Up to the previous recommendations, no data were available on herpes zoster vaccination in patients with AIIRD. Since 2010 seven relevant studies have been published (table 10).

Currently, two different vaccines are available for the prevention of herpes zoster in varicella-zoster virus (VZV)-seropositive healthy adults above the age of 50 years: one is a live-attenuated vaccine and the other is an adjuvanted subunit (non-live) vaccine. All studies on zoster vaccination in patients with AIIRD have been performed using the live-attenuated zoster vaccine. This vaccine has
| First author + ref. | Year | Study design | No. cases | Efficacy | Immunogenicity | Safety | Influence IS on eff./imm. | LoE Eff. Imm. Saf. |
|---------------------|------|--------------|-----------|----------|----------------|--------|--------------------------|----------------|
| Winthrop170          | 2017 | RCT         | 55 RA MTX+TFC* 57 RA MTX+PCB* | – | Similar CMI response. Trend towards higher humoral response MTX+TFC | 3 SAE in MTX-TFC group versus 0 in MTX+PCB: one cholangitis, one bronchitis and one disseminated primary varicella in seronegative patient. Mild AE no difference. | See column immunogenicity. | – 2b 4 |
| Russell173           | 2015 | RCT         | 206 GC vacc. (25% PMR) 100 GC PCB-vacc (31% PMR) Mostly no AIIRD. >10–20 mg: n=39 | – | Higher postvacc. humoral response in vacc. | More injection-site AE and headache in vacc. Other systemic and serious AE: no difference. | No influence of limited daily GC dose | – 2b 4 |
| Koh169               | 2018 | Cohort     | 41 RA 28 OA | – | Lower CMI response in RA. Similar humoral response. | No SAE. Mild systemic AE in 11.6% of all participants. 6 RA flares during 12 weeks postvacc. Median Disease Activity Index unchanged. | – – 2b 4 |
| Zhang167 and Yun168  | 20122017 | Cohort (retrospective database) | Total: 463 541 Vacc: 18 683 (4.0%) Vacc on biologics: 633 7780 vaccinated patients in analysis | Lower incidence of HZ in vacc. patients. Rapid decline difference incidence rate vacc. and unvacc. 6 years postvacc: no longer significant. | – <42 of vacc: HZ incidence decreased, no cases of hospitalised meningitis or encephalitis, no HZ in patients using biologics | Lower HZ incidence in vacc. patients, using biologics, DMARDs or GC alone | 2b – 4 |
| Guthridge171         | 2013 | Cohort     | 10 SLE 10 HC | – | Similar proportion of subjects with 50% increase in CMI measures postvacc. | No difference. No flares. | – – 2b 4 |

* Tofacitinib or placebo was started 2–3 weeks postvaccination.
† Patients with rheumatoid arthritis (n=292 169), psoriasis (n=89 565), psoriatic arthritis (n=11 030), ankylosing spondylitis (n=4026) and/or inflammatory bowel disease (n=66 751).
AIIRD, auto-immune inflammatory rheumatic disease; CMI, cell-mediated immunity; DMARD, disease-modifying antirheumatic drug; eff., efficacy; GC, glucocorticoids; HC, healthy controls; HZ, herpes zoster; imm., immunogenicity; IS, immunosuppressives; LoE, Level of evidence; MTX, methotrexate; No., number; OA, osteoarthritis; PCB, placebo; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; RCT, randomised controlled trial; ref., reference; (S)AE, serious adverse event(s); Saf., safety; SLE, systemic lupus erythematosus; TFC, tofacitinib; vacc., vaccinated.
been shown to decrease the risk of herpes zoster in adults above the age of 50 years by 38%–70%,\textsuperscript{161,162} with lowest efficacy in those above 70 years.\textsuperscript{161} Of note, the AS01 adjuvanted subunit (non-live) vaccine has recently been shown to be safe and more efficacious than the live-attenuated vaccine in healthy adults above the age of 50 and 70 years.\textsuperscript{163,164} Vaccine efficacy ranged between 91% and 98% and did not significantly differ between age groups.\textsuperscript{163,164} Of note, safety of the adjuvant system AS01, which contributes to the generation of a particularly strong cellular immune response,\textsuperscript{165,166} has not yet been determined in patients with AIIRD.

Vaccination with the live-attenuated zoster vaccine was associated with a reduced incidence of herpes zoster in patients with immune-mediated diseases (RA, psoriatic arthritis, ankylosing spondylitis, psoriasis and inflammatory bowel diseases) over 60 years of age, as reported in a large retrospective database study by Zhang et al. In total, 7780 vaccinated and over 800,000 unvaccinated patients were included in their analysis.\textsuperscript{167} A rapid decline in vaccine efficacy was observed in the same study population. Six years after vaccination, the difference in herpes zoster incidence between groups of vaccinated and unvaccinated subjects was no longer significant.\textsuperscript{168}

Immunogenicity of the live-attenuated zoster vaccine has been investigated in patients with RA\textsuperscript{169,170} and SLE.\textsuperscript{171} Both patient groups were able to mount cell-mediated immune responses to the vaccine,\textsuperscript{169-171} which is crucial for the protection against herpes zoster.\textsuperscript{172} However, live-attenuated zoster vaccination resulted in lower cell-mediated immunity in patients with RA (n=41) than in controls (n=28).\textsuperscript{169} Because no correlate of protection for herpes zoster infection is known, and methods for assessing herpes zoster immunity are not uniform, interpretation and comparison of studies is difficult.

Disease activity of the underlying AIIRD did not seem to be affected by live zoster vaccination, but numbers of analysed patients are low.\textsuperscript{169-171} In a study in patients with RA, who were randomised to receive tofacitinib (n=55) or placebo (n=57) 2–3 weeks following vaccination, three serious adverse events were observed in the tofacitinib group versus none in the placebo group. Of note, one case of disseminated primary varicella occurred in a patient who was VZV-seronegative at baseline.\textsuperscript{170} In the retrospective database study by Zhang et al, the zoster vaccine did not seem to induce infection within 42 days after vaccination. On the contrary: a reduced incidence of herpes zoster was seen in the vaccinated patients. No cases of hospitalised meningitis or encephalitis were identified in this period.\textsuperscript{167}

Influence of immunomodulating agents

The favourable effect of vaccination on herpes zoster incidence in patients with autoimmune diseases is present regardless of medication use, including biologics (used by 633 vaccinated patients), as reported in the same large database study by Zhang et al.\textsuperscript{167} A daily dose of 5–20 mg of corticosteroids in a heterogeneous patient group (206 patients received zoster vaccination, of whom 25% were patients with polymyalgia rheumatica) did not seem to affect humoral immune response to live-attenuated zoster vaccination. Unfortunately, effect on cell-mediated immune response was not reported.\textsuperscript{173} Zoster vaccination resulted in a similar cell-mediated response in patients with RA who started the use of tofacitinib or placebo 2–3 weeks after vaccination (see table 10).\textsuperscript{170}

Summary and clinical implications

Although large prospective trials that are sufficiently powered for assessing safety are lacking, the safety and efficacy profile of the live-attenuated zoster vaccine seem to be favourable for VZV-seropositive patients with AIIRD. However, the vaccine contains live-attenuated virus and, therefore, should still be considered with caution in the immunocompromised patient. Before administering the zoster vaccine, it is advisable to affirm the VZV-seropositive status of the patient. In case of a VZV-seronegative patient, a less potent VZV vaccine approved for preventing primary varicella in children may be considered. Based on expert opinion, the zoster vaccine is preferably administered 4 weeks prior to initiation and not during treatment with biologics and targeted synthetic DMARDs.

As noted earlier, the novel non-live AS01 adjuvanted subunit vaccine has been shown to be more efficacious than the live-attenuated vaccine in healthy adults above the age of 50–70 years. Whether this also holds true for the AIIRD population and whether the adjuvant system AS01 is safe in this patient group, is most interesting and warrants further investigation.

Yellow fever vaccination

Efficacy—immunogenicity—safety

The yellow fever vaccine is a live-attenuated vaccine. Several cases of visceral dissemination of yellow fever of the vaccine type have been reported, with clinical features similar to wild type yellow fever, including high mortality.\textsuperscript{174-176} The vaccine is therefore generally contraindicated in immunocompromised patients\textsuperscript{177-180} (online supplementary table S3).

Only limited observational studies have been published on yellow fever vaccination in patients with AIIRD, mostly concerning revaccination (see online supplementary table S3 for details). The reported immunogenicity results are mainly adequate, and similar as in HC.\textsuperscript{177-180} A study of 34 glucocorticoid-treated patients (among whom 9 were patients with RA and 14 with chronic inflammatory conditions, revaccination in 44%) and 68 HC, reported more moderate and severe local reactions in patients (12% vs 2%).\textsuperscript{179} No serious systemic adverse events of yellow fever vaccination were reported in the previously mentioned studies in patients with AIIRD. As the vaccine has been contraindicated in immunocompromised patients for years, numbers of studies and included patients are however very low and, as stated, most patients were revaccinated. Of note, lethal outcomes of fellow
fever vaccination have been reported in immunocompromised patients, including a female patient with RA and SLE, who was possibly treated with glucocorticoids and MTX.\(^\text{181}\)

**Influence of immunomodulating agents**

Due to the heterogeneous populations of the small studies on yellow fever vaccination in patients with AIIRD, it is difficult to discern the separate influences of different immunosuppressive agents. In a study of corticosteroid-treated patients, of whom 44% were vaccinated for yellow fever earlier in life, seroprotection against yellow fever was reached in all 20 analysed patients. A trend towards a lower yellow fever antibody response was observed in anti-TNFα-treated patients with RA (n=17) compared with HC (n=15).\(^\text{180}\)

**Summary and clinical implications**

Reported immunogenicity results of yellow fever revaccination among patients with AIIRD are mainly adequate and similar as in HC. However, the available data on the safety of yellow fever vaccination in this group are very limited, and potential sequelae are serious (including death). Patients with AIIRD under immunosuppression should, therefore, avoid yellow fever vaccination in general. Temporarily withholding immunosuppressive therapy may be considered for patients with AIIRD travelling to endemic countries.

**Human papillomavirus vaccination**

**Efficacy—immunogenicity—safety**

Data on the efficacy of human papillomavirus (HPV) vaccination originate from vaccine trials in HCs that investigate the capacity of HPV vaccination to prevent premalignant lesions. A vaccine efficacy of 66% to prevent cervical intraepithelial neoplasia grade III was reported in a bivalent (HPV types 16 and 18) HPV vaccine trial after 4.5–10 years of follow-up.\(^\text{182}\)

The correlation between the level of anti-HPV antibodies and protection against the development of cervical carcinoma is not known, since there are no reports on cervical carcinoma in vaccinated subjects. The level of seroprotection is based on comparison with naturally infected subjects.\(^\text{183}\)

To date, no studies on the efficacy of HPV vaccination to prevent malignancies or premalignant lesions in the AIIRD population have been published, but there are studies on HPV vaccine immunogenicity in patients with AIIRD, all published after 2010 (online supplementary table S4). All but one study, performed in patients with juvenile idiopathic arthritis (JIA),\(^\text{184}\) include patients with SLE and used a quadrivalent (HPV types 6, 11, 16 and 18) vaccine.\(^\text{185–189}\) Seroconversion rates in patients were high and usually similar to those of healthy subjects, although two studies reported a lower geometrical mean titre for HPV 16 in patients with SLE after 5 years of follow-up,\(^\text{185}\) and also for patients with JIA,\(^\text{184}\) compared with HCs.

Rates of vaccine adverse events similar to HCs were reported for both patients with SLE\(^\text{188}\) and patients with JIA.\(^\text{184}\) Disease activity after vaccination was stable.\(^\text{184 186 188 189}\)

**Influence of immunomodulating agents**

Mok et al reported that anti-HPV titres were lower in vaccinated patients with SLE using immunosuppressive agents, especially in those receiving a combination of mycophenolate mofetil (MMF) and glucocorticoids.\(^\text{188}\) After 5 years of follow-up it was noted that patients with SLE that no longer were anti-HPV seropositive received significantly longer and higher doses of glucocorticoids and MMF than those with persistent seropositivity.\(^\text{185}\)

**Summary and clinical implications**

Immunogenicity of HPV vaccination in the AIIRD population is high and, in the majority of studies, similar to that in HCs. The vaccine appears to be safe in patients with AIIRD. Therefore, the vaccine is recommended for patients with AIIRD, in accordance with recommendations for the general population. Patients with SLE, in particular, are advised to receive HPV vaccination, since they were shown to be at high risk of contracting a genital HPV infection, including the serotypes that are considered to be high risk for developing cervical dysplasia.\(^\text{190–194}\)

**Tickborne encephalitis vaccination**

**Efficacy—immunogenicity—safety**

The available tickborne encephalitis (TBE) vaccines are inactivated vaccines. The vaccine is highly immunogenic in the general adult population.\(^\text{195}\) Excellent effectiveness of TBE vaccination in prevention of TBE was demonstrated in an Austrian study.\(^\text{196}\) Nonetheless, cases of vaccine failure have been reported, which occurred mainly in older or immunocompromised persons.\(^\text{197}\)

To date, only one study on vaccination against TBE in patients with AIIRD has been published (online supplementary table S5). This Swedish study by Hertzell et al enrolled 65 patients with RA and 1 patient with AS on anti-TNF (n=16), a combination of MTX and anti-TNF (n=36) or MTX alone (n=14). Four doses of vaccine instead of three were offered to patients and HCs ≥60 years of age. One month after the last dose of vaccine, 39% of the patients and 79% of the HCs had developed protective levels of neutralising TBE antibodies. The difference was statistically significant. An extra dose of vaccine in patients with an undetectable antibody level at month 13 resulted in seroprotection in 4 out of 10 patients, all of whom were older than 60 years. No serious adverse events occurred.\(^\text{198}\)

**Influence of immunomodulating agents**

In the study by Hertzell et al, regarding only patients ≥60 years of age, it seemed that a lower percentage of those treated with a combination of MTX and anti-TNF reached seroprotective anti-TBE levels than those treated with MTX or anti-TNF alone (25% vs 38%–40%).\(^\text{198}\)
Summary and clinical implications

Although the updated recommendations do not specifically provide recommendations regarding TBE vaccination, an overarching principle states that non-live vaccines can be administered to patients with AIIRD, including during their use of glucocorticoids and DMARDs. The only available study on TBE vaccination in the AIIRD patient population showed a diminished immunogenicity response in these patients. As such, determining TBE-antibody levels after the last vaccine dose and, if necessary, giving an extra dose of vaccine may be considered.

DISCUSSION

This SLR summarises the available data on efficacy, immunogenicity and safety of vaccination in patients with AIIRD, including patients with AIIRD using immunomodulating agents. Since the first version of EULAR recommendations and accompanying SLR on vaccination of adult patients with AIIRD were published in 2011,2-142 there has been a large expansion in the amount of available evidence on this topic, necessitating an update. By defining four research questions, we were able to address incidence/prevalence of VPIs, efficacy, immunogenicity and safety of vaccination, as well as the influence of immunomodulating agents on vaccine efficacy/immunogenicity in patients with AIIRD. To enable the presentation of a clear overview of the large amount of available data, the evidence on the incidence and prevalence of VPI diseases in patients with AIIRD was presented in a separate SLR, which was submitted for publication simultaneously with this report. The literature search for the fourth research question, dealing with the effect of vaccinating household members of patients with AIIRD on the occurrence of VPI in these patients and household members (including newborns), did not result in finding any relevant studies. Therefore, the recommendation encouraging household members of patients with AIIRD to receive vaccines according to national guidelines with the exception of oral polio vaccine, as formulated in the updated recommendations, is based on expert opinion. This recommendation follows guidelines of international societies such as the Infectious Diseases Society of America.199 Also the recommendation of avoiding live-attenuated vaccines during the first 6 months of life in newborns of mothers treated with biologics during the second half of pregnancy is based on expert opinion. This recommendation is in line with the EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.200

One strength of our current approach, compared with the 2011 SLR, is the clear separation between efficacy and immunogenicity of vaccination, allowing a just interpretation of the data by readers. When assessing the different vaccines, evidence on efficacy, defined as the capacity of a vaccine to prevent infection, was considered to be of higher quality than evidence on immunogenicity, which refers to the capacity of vaccines to induce humoral and/or cellular immune responses. Unfortunately, because of the necessarily large sample size, using a clinical end point was essentially infeasible for some groups of AIIRD and/or vaccines. Consequently, only a small number of studies used a clinical end point.

It is important to note that although a large number of articles was included, for certain AIIRDs, vaccines and immunomodulating treatments the number of publications was still very limited. The majority of studies was performed in patients with RA and SLE. Results in these patient groups cannot uncontestedly be extrapolated one on one to patients with other AIIRDS.

Regarding safety of vaccination in the AIIRD population, both the occurrence of adverse events and influence on underlying disease of vaccination were assessed. Although since 2011 the amount of available evidence has considerably grown, studying safety of vaccination in patients with AIIRD remains a challenge. While vaccination did not lead to significant harms in the large majority of the included studies, these studies were too small or not properly designed to be able to detect the occurrence of rare adverse events.

In conclusion, evidence on efficacy, immunogenicity and safety of vaccination in patients with AIIRD (including those using immunomodulation agents), from October 2009 to August 2018, was systematically reviewed to provide a basis for updated evidence-based recommendations for vaccination in patients with AIIRD,3 in order to aid physicians, nurses and other health professionals dealing with questions regarding vaccination in patients with AIIRD in daily clinical practice.

Author affiliations

Medical microbiology and infection prevention, UMCG, Groningen, The Netherlands
Rheumatology and Clinical Immunology, UMCG, Groningen, The Netherlands
Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Faculty of Medicine, Tel Aviv University Sackler, Tel Aviv, Israel
Internal Medicine and Allergology, Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands
Zabulowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
Internal Medicine, Martini Hospital, Groningen, The Netherlands
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands
Dipartimento di Medicina Clinica e Molecolare, Sapienza University of Rome, Roma, Italy
Hospital Cochin, Rheumatology, Université Paris Descartes, Paris, France
Clinical epidemiology and biostatistics, PRES Sorbonne Paris- Cité, Paris, France
Department of Clinical Sciences, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden
Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Rheumatology, Zuyderland Medical Centre, Sittard-Geleen - Heerlen, The Netherlands
Rheumatology and Clinical Immunology, Giessen University, Giessen, Germany
Incidence and prevalence of vaccine preventable infections in adults with autoimmune inflammatory rheumatic diseases (AIIRD): a systematic literature review Informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open 2019.

2. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414–22.

3. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215882. [Epub ahead of print: 14 Aug 2019].

4. van der Heijde D, Aletaha D, van den Heuvel E, et al. Effect of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272–9.

5. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272–9.

6. Denman EJ, Denman AM, Greenwood BM, et al. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis 1970;29:220–31.

7. Kapetanovic MC, Saxne T, Nilsson J-A, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007;46:608–11.

8. Kubota N, Nii T, Nanki T, et al. Anti-Tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007;17:53–5.

9. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937–41.

10. Nii T, Kubota N, Nanki T, et al. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol 2009;19:216–8.

11. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75–81.

12. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191–4.

13. Gielnik LB, van der Bijl AE, Beyer WEP, et al. The effect of anti-TNF necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713–6.

14. Herron A, Dettefl G, Dixon B, et al. Influenza vaccination in patients with rheumatic diseases. safety and efficacy. JAMA 1979;242:53–6.

15. Turner-Stokes L, Cambridge G, Corcoran T, et al. In vitro response to influenza immunization by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988;47:532–5.

16. Del Porto F, Laganà B, Biserilà R, et al. Influenza vaccination in patients with systemic lupus erythematosus and rheumatoid arthritis. safety and immunogenicity. Vaccine 2006;24:3217–23.

17. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010;39:442–7.

18. Williams GW, Steinberg AD, Reinersen JL, et al. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med 1978;88:729–34.

19. Blustow SC, Douglas RG, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978;88:786–9.

20. Brodman R, Gillfllin R, Glass D, et al. Influenza vaccine response in systemic lupus erythematosus. Ann Intern Med 1978;88:735–40.

21. Louie JS, Nies KL, Schonbrun D, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978;88:790–2.

22. Pons VG, Reinersen JL, Steinberg AD, et al. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Viral 1979;4:15–23.

23. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002;29:2555–7.

24. Mercado U, Acosta H, Avendaño L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Investig Clin 2004;56:16–20.

25. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccine in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913–8.

26. Węsick-Szewczyk E, Romanowska M, Michnik P, et al. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010;29:605–13.

27. Holvast A, Stegeman CA, Benne CA, et al. Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009;68:873–8.

28. Zycinska K, Romanowska M, Nowak I, et al. Antibody response to inactivated subunit influenza vaccine in patients with Wegener’s granulomatosis. J Physiol Pharmacol 2007;58(Suppl 2):819–28.

29. Setti M, Fengo Glioni D, Ansaldi F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and...
immunological parameters in scleroderma patients. Vaccine 2009;27:3367–72.
33. Gelincik LBS, Teng YKO, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007;66:402–3.
34. Chen C-M, Chen H-J, Chen W-S, et al. Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis. Int J Rheum Dis 2018;21:1246–53.
35. Chang C-C, Chang Y-S, Chen W-S, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study. Sci Rep 2016;6:37817.
36. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013;42:445–50.
37. Milanovic M, Stojanovich L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med 2013;229:29–34.
38. Arad U, Tzokas A, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643–8.
39. Jain VK, Bhashini N, Balaje LK, et al. Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis. Indian J Med Res 2011;133:498–502.
40. Jain VK, Bhashini N, Balaje LK, et al. Safety and efficacy of influenza vaccine in rheumatoid arthritis enrolled in a large observational cohort. Acta Reumatol Port 2009;34:498–502.
41. Kobie JJ, Zheng B, Bryk P, et al. Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factor. Arthritis Res Ther 2011;13:13.
42. Milanetti F, Gerbasi V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009–10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014;177:287–94.
43. Huang Y, Wang H, Tam WWS. Is rheumatoid arthritis associated with reduced immunogenicity of the influenza vaccination? A systematic review and meta-analysis. Curr Med Res Opin 2017;33:1901–8.
44. Wallin L, Quintilio W, Locatelli F, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2014;33:181–6.
45. Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum 2011;63:2386–401.
46. Pugas M, Biscay P, Barnetche T, et al. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis. Rheumatology 2016;55:1664–72.
47. Liao Z, Tang H, Xu X, et al. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a meta-analysis. PLoS One 2016;11:e0147856.
48. Huang Y, Wang H, Wan L, et al. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccines? Arthritis Res Ther 2017;19:1–7.
49. Jeffs LS, Peh CA, Jose MD, et al. Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Nephrology 2015;20:343–51.
50. Litinsky I, Balbir A, Zisman D, et al. Vaccination against influenza in patients with systemic sclerosis. Clin Exp Rheumatol 2012;30:2 Suppl 71:57–11.
51. Polack AF, Lingorbo K, Mader-Balakirski N, et al. Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. Clin Exp Rheumatol 2015;33:181–6.
52. Caso F, Ramonda R, Del Puente A, et al. Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF-α therapy. Clin Exp Rheumatol 2015;33:507–12.
53. Kostianovsky A, Charles P, Alves J-F, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012;30(1 Suppl 70):S83–9.
54. Jäger VK, Hoffman HM, van der Poll T, et al. Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. Rheumatology 2017;56:1484–91.
55. Saad CGS, Borba EF, Akawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068–73.
56. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the A/H1N1 non-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011;63:1486–96.
57. Miraglia JL, Abdalla E, Hoff PM, et al. Immunogenicity and reactivity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 2011;6:e27214.
58. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 2011;63:1080–7.
59. Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Ann Rheum Dis 2011;70:2144–7.
60. Adler S, Krivina A, Weikum JS, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease–a prospectively controlled vaccination study. Rheumatology 2012;51:695–700.
61. Franca ILA, Ribeiro ACM, Akawa NE, et al. Tnf blockers show distinct patterns of immune response to the pandemic influenza A/H1N1 vaccine in inflammatory arthritis patients. Rheumatology 2012;51:2091–8.
62. Iwamoto M, Homma S, Onishi S, et al. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 2010;30:1839–43.
63. Kapetanovic MC, Kristensen L-E, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014;16:144.
64. Lu C-C, Wang Y-C, Lai J-H, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: safety and immunity. Vaccine 2011;29:444–50.
65. Borba EF, Saad CGS, Pasado SG, et al. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology 2012;51:1061–9.
66. Shinjo SK, de Moraes JCB, Levy-Neto M, et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: immunogenicity independent of therapy and NO harmful effect in disease. Vaccine 2012;31:202–6.
67. Miossi R, Fuller R, Moraes JCB, et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics 2013;68:129–33.
68. Brauner S, Folkersen L, Kvarnström M, et al. H1N1 vaccination in Sjögren’s syndrome triggers polyclonal B cell activation and promotes autoantibody production. Ann Rheum Dis 2017;76:1755–63.
69. Sampaio-Barros PD, Andrade DCO, Seguro LCP, et al. Pandemic non-adjuvanted influenza A H1N1 vaccine in a cohort of patients with systemic sclerosis. Rheumatol Int 2012;32:1721–5.
70. Mathian A, Devilliers H, Krivina A, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011;63:3003–11.
71. Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009;48:1294–9.
72. Saleri S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: safety and immunogenicity. Clin Immunol 2010;134:113–20.
73. Kogure T, Harada N, Oka Y, et al. The observation of humoral responses after influenza vaccination in patients with rheumatoid arthritis treated with Japanese Oriental (Kampo) medicine: an observational study. Evidence-Based Complementary and Alternative Medicine 2012;2012:1–6.
74. Mori S, Ueki Y, Hirakata N, et al. Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis. Ann Rheum Dis 2012;71:2006–10.
75. Kogure T, Harada N, Tatsumi T, et al. Investigation of clinical characteristics as predictive factors for the humoral immune response to the influenza vaccine in patients with rheumatoid arthritis. Clin Rheumatol 2014;33:323–9.
76. Subesinghe S, Behkan M, Rutherford AI, et al. A systematic review and Metaanalysis of antirheumatic drugs and vaccine
119. Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab. *Arthritis Res Ther* 2015;17.

120. Izumi Y, Akazawa M, Akeda Y, et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. *Arthritis Res Ther* 2017;19.

121. Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis* 2011;70:1289–91.

122. Nagel J, Geborek P, Saxne T, et al. The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients. *Scand J Rheumatol* 2015;44:271–9.

123. Nagel J, Geborek P, Saxne T, et al. The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients. *Arthritis Res Ther* 2015;17.

124. Migita K, Akeda Y, Akazawa M, et al. Opsopic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patient receiving golimumab plus methotrexate. *Medicine* 2015;94:e2184.

125. Chatham W, Chadha A, Fettplace J, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autobody-positive systemic lupus erythematosus. *Lupus* 2017;26:1483–90.

126. Walker UA, Huffman HM, Williams R, et al. Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associated Periodic Syndromes. *Arthritis Rheumatol* 2016;68:516–20.

127. Cmikic Kapetanovic M, Saxne T, Truedsson L, et al. Persistence of antibody responses 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. *Arthritis Res Ther* 2013;15.

128. Grabar S, Groh M, Bahauud M, et al. Pneumococcal vaccination in patients with systemic lupus erythematosus: a multicenter placebo-controlled randomized double-blind study. *Vaccine* 2017;35:4877–85.

129. Rákóczi Éva, Beaudouin-Bazir, et al. Immunogenicity and safety of pneumococcal vaccination in patients with systemic sclerosis. *Rheumatology* 2018;57:625–30.

130. Groh M, Puéchal X, Terrier B, et al. Failure of pneumococcal immunization during remission induction treatment of ANCA-associated vasculitis: the Pneumovax pilot 1 study. *Joint Bone Spine* 2017;84:643–4.

131. Bahauud M, Beaudouin-Bazir C, Husson M, et al. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. *Hum Vaccin Immunother* 2018;14:1464–70.

132. Alyasian S, Adab M, Hosseinpour A, et al. Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus. *Ir J Immunol* 2016;13:204–19.

133. Esposito S, Bonanni P, Maggi S, et al. Recommended immunization schedules for adults: clinical practice guidelines by the ESCMID vaccine Study Group (EUVASG), European geriatric medicine Society (EUGMS) and the world association for infectious diseases and immunological disorders (WAiD). *Hum Vaccin Immunother* 2016;12:1–18.

134. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. *Vaccine* 2014;32:2364–74.

135. Jackson LA, Gurtman A, van Cleef M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. *Vaccine* 2013;31:3594–602.

136. Espirt P, Pérez M, Golina J-M, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. *AIDS* 2007;21:2425–34.

137. Kobayashi M, Bennett MR, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on immunization practices (ACIP). *MMWR Morb Mortal Wkly Rep* 2015;64:944–7.

138. Verschueren A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis a vaccine in healthy children. *N Engl J Med* 1992;327:453–7.

139. Innis BL et al. Protection against hepatitis A by an inactivated vaccine. *JAMA* 1994;271:1328–34.

140. van Assen S, El Kamay O, Agmon-Levin N, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League against rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. *Autoimmun Rev* 2011;10:341–52.

141. Orr N, Klement E, Gillis D, et al. Long-Term immunity in young adults after a single dose of inactivated hepatitis A vaccines. *Vaccine* 2006;24:4328–32.

142. Schmidtké P, Habermehl P, Knuf M, et al. Cell mediated and antibody immune response to inactivated hepatitis a vaccine. *Vaccine* 2005;23:5127–32.

143. Asking HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. *Travel Med Infect Dis* 2014;12:134–42.

144. Rosdahl A, Herzog C, Frösner G, et al. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression - A prospective, open-label, multi-center study. *Travel Med Infect Dis* 2018;21:43–50.

145. van den Bijnster W, Siex HM, Tonty-koek C, et al. Seroprotection after hepatitis A vaccination in patients with Drug-Induced immunosuppression. *J Travel Med* 2013;20:278–82.

146. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. *N Engl J Med* 2004;351:2382–8.

147. Jack AD, Hall AJ, Maj M, et al. What level of hepatitis B antibody is protective? *J Infect* 1999;179:489–92.

148. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002;61:623–5.

149. Kuruma KAM, Borba EF, Lopes M, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. *Lupus* 2007;16:350–4.

150. Franco Salinas G, de Rycke L, Cantaert T, et al. Tfn blockade impairs T cell dependent antibody responses. *Ann Rheum Dis* 2008;67(suppl 3).

151. Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet’s disease. *J Gastroenterol Hepatol* 2005;20:1508–11.

152. Intongkam S, Samakarnthai P, Pakchotaron R, et al. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. *JCR: Journal of Clinical Rheumatology* 2018.

153. Scheibel I. The uses and results of active tetanus immunization. *Bull World Health Organ* 1955;15:919–94.

154. Roush SW, Murphy TV. Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. *JAMA* 2007;298:2155–63.

155. Dewey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. *Clin Exp Immunol* 1987;68:562–9.

156. Abe T, Homma M. Immunological reactivity in patients with systemic lupus erythematosus: humoral antibody and cellular immune responses. *Acta Rheumatol Scand* 1971;17:35–46.

157. Kaschef S, Ghazizadeh F, Derakhshan A, et al. Antigen-Specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. *Ir J Immunol* 2008;5:181–4.

158. Nies K, Boyer R, Stevens R, et al. Anti-Tetanus toxoid antibody synthesis after booster immunization in systemic lupus erythematosus. Comparison of the in vitro and in vivo responses. *Arthritis Rheum* 1980;23:1343–50.

159. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. *N Engl J Med* Overseas Ed 2005;352:2271–84.

160. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. *Clinical Infectious Diseases* 2012;54:922–8.

161. Lat H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. *N Engl J Med* 2015;372:2087–96.
164. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019–32.

165. Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human herpes zoster virus (VZV) adjuvant AS01 depends on activated dendritic cells. J. Vi. 2014;193:2019–30.

166. Fochesato M, Dendouga N, Boxus M. Comparative preclinical evaluation of AS01 versus other adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine. Hum Vacc Immunother 2016;12:2092–6.

167. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. J Rheumatol 2017;44:1083–7.

168. Koh BH, Lee J, Kim SH, et al. Safety, and humoral and cell-mediated immune responses to herpes zoster vaccine in patients with rheumatoid arthritis. J Rheumatol 2018;45:659–65.

169. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccine in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol 2017;69:1036–45.

170. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccine in STE: a pilot study of immunogenicity. J Rheumatol 2013;40:1875–80.

171. Gershon AA, Breuer J, Cohen J, et al. Varicella zoster virus infection. Nat Rev Dis Primers 2015;1.

172. Russell AF, Gershon AA, Parrino J, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/ maintenance corticosteroids. Vaccine 2015;33:3129–34.

173. de Menezes Martins R, Fernandes Leal Mdal, Homma A. Serious adverse events associated with yellow fever vaccine. Hum Vacc Immunother 2015;11:2183–7.

174. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccine: a report of four cases. The Lancet 2001;358:98–104.

175. Vasconcelos P, Luana E, Gailer R, et al. Serious adverse events associated with yellow fever 17D vaccine in Brazil: a report of two cases. The Lancet 2001;358:91–7.

176. Wieten RW, Gooihs A, Jonker EFF, et al. 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients. J Infect 2016;72:713–22.

177. Oliveira ACV, Mota MLH, Santos-Neto LL, et al. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants. v017;69:1989–77.

178. Kernis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: an observational cohort study. Arthritis Care Res 2013;65:1522–33.

179. Scheinberg M, Guedes-Barbosa LS, Manqueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res 2010;62:897–6.

180. Whittembury A, Ramirez G, Hernández H, et al. Viscerotrophic disease following yellow fever vaccination in Peru. Vaccine 2009;27:5974–81.

181. Lehtinen M, Laggathed C, Luostarinen T, et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials. BMJ Open 2017;7:801596.

182. Dauner JG, Pan Y, Hildesheim A, et al. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010;28:3497–13.

183. Esposito S, Corona F, Barzon L, et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. Expert Rev Vaccines 2014;13:1387–93.

184. Fok CC, Ho DP, CH. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine 2018;36:3301–7.

185. Dhar JP, Essermacher L, Dhar R, et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 2017;35:264–6.

186. Dhar JP, Essermacher L, Dhar R, et al. The effect of history of abnormal Pap smear or preceding HPV infection on the humoral immune response to quadrivalent human papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus. Hum Vacc Immunother 2018;14:2318–22.

187. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis 2013;72:659–64.

188. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatric Rheumatology 2013:11.

189. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010;19:1485–91.

190. Lee Y-H, Cho J-Y, Park S-H, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci 2010;25:1431–7.

191. Lyco L, Grassi MFR, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Lupus 2012;18:944–51.

192. Méndez-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, et al. Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women. Lupus 2017;26:941–5.

193. Méndez-Martínez S, Garcia-Carrasco M, Jiménez-Herrera EA, et al. Factors of the epidemiological triad that influence the persistence of human papilloma virus infection in women with systemic lupus erythematosus. Lupus 2015;24:1736–42.

194. Kollaritsch H, Paulke-Korinek M, Holzmann H, et al. Vaccines and vaccination against tick-borne encephalitis. Expert Rev Vaccines 2012;11:1103–19.

195. Heinz FK, Holzmann H, Essl A, et al. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine 2007;25:7559–67.

196. Andersson CR, Vene S, Insulander M, et al. Vaccine failure after active immunisation against tick-borne encephalitis. Vaccine 2010;28:2827–31.

197. Herzel KB, Paukens K, Romolo L, et al. Tick-Borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Vaccine 2016;34:650–5.

198. Rubín LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2013;2014:309–18.

199. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810.

200. Brünecker GR, Landewé R, Genovese MC, et al. Vaccines, pregnancy, and during pregnancy and lactation. Autoimmunity 2013;2014:309–18.

201. Goetzman Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795–810.

202. Klubertanz A, Chechtmann J, Teate M, et al. Vaccine responses in patients with rheumatoid arthritis treated with Certolizumab pegol: results from a single-blind randomized phase IV trial. J Rheumatol 2014;41:648–57.

203. Luque Ramos A, Hoffmann F, Callhoff J, et al. Influenza and pneumococcal vaccination in patients with rheumatoid arthritis in comparison with age- and sex-matched controls: results of a claims data analysis. Rheumatol Int 2016;36:1255–63.

204. Launay O, Paul S, Servetaz A, et al. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. Vaccine 2013;31:3492–501.

205. Vista ES, Crowe SR, Thomson LP, et al. Influenza vaccination can induce new-onset antiphospholipid antibodies but not [2-glycoprotein-I] antibodies among patients with systemic lupus erythematosus. Lupus 2012;21:168–74.

206. Muller RB, Mairer R, Hoschler K, et al. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol 2013;31:723–30.

207. Urowitz MB, Anton A, Ibanez D, et al. Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. Arthritis Care Res 2011;63:1517–20.

208. de Medeiros DM, Silva CA, Bueno C, et al. Pandemic influenza immunization in primary antiphospholipid syndrome (PAPS): a trigger to thrombosis and autoantibody production? Lupus 2014;23:1412–6.